Adrián Mosquera Orgueira, MD, PhD,

Adrián Mosquera Orgueira, MD, PhD, is a specialist in Hematology and Hemotherapy and lead researcher of the Computational and Genomic Hematology Group at the Health Research Institute of Santiago de Compostela.

Articles by Adrián Mosquera Orgueira, MD, PhD,

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

ByAdrián Mosquera Orgueira, MD, PhD,

May 29th 2025

Dr Orgueira on Refining the Use of Machine Learning to Predict Survival Outcomes After Transplant in Myelofibrosis

ByAdrián Mosquera Orgueira, MD, PhD,

May 19th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses research to improve machine learning models for predicting post-transplant survival outcomes in myelofibrosis.

Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis

ByAdrián Mosquera Orgueira, MD, PhD,

April 15th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses whether machine learning could accurately predict OS and NRM outcomes after allo-HSCT in myelofibrosis.

Adrián Mosquera Orgueira, MD, PhD,

Articles by Adrián Mosquera Orgueira, MD, PhD,

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

Dr Orgueira on Refining the Use of Machine Learning to Predict Survival Outcomes After Transplant in Myelofibrosis

Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis

Latest Updated Articles

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies